Imagine trying to sew a precise stitch inside a blood vessel using a tiny needle, but doing it through a small tube instead of open surgery. This technology acts like a smart sewing machine for arteries, closing large holes with a simple button click. It replaces manual stitching with a reliable, automated pattern to stop bleeding faster.
Large-bore transcatheter procedures often leave access sites that are difficult to close, leading to bleeding complications in up to 20% of cases and high management costs.
A Class III medical device for large-bore vascular closure featuring a proprietary micro-suturing system. Deliverables include a production line in a Class 7 clean room and validated article systems.
If you are a tool manufacturer dealing with high complication rates in vascular closure—which can reach 20%—this project developed a micro-suturing device that could reduce those complications to 3%. This allows for safer, faster procedures and better patient outcomes.
If you are a clinic dealing with high costs of complication management, around 20k per patient, this project developed a closure device that enables same-day discharge. This reduces hospital stay durations and lowers overall healthcare costs.
If you are a company developing larger transcatheter devices that require access sites up to 30Fr, this project developed a versatile closure platform. It ensures that larger bore access does not lead to increased bleeding risks.
It aims to reduce healthcare costs by enabling same-day discharge and avoiding complication management costs, which currently average 20k per patient.
Yes, the platform is designed for scalability; while the first product focuses on vascular access, future applications include repairing intracardiac structures like Patent Foramen Ovale (PFO).
Based on available project data, the company has developed a proprietary micro-suturing technology, though specific licensing terms are not disclosed.
The device is categorized as a Class III medical device and requires the completion of clinical trials to obtain CE certification.
The project is currently preparing to initiate First-In-Human (FIH) clinical trials following the completion of preclinical studies in early 2025.
The project is led by a single Israeli SME, Novelrad Ltd, which holds 100% of the industry ratio. This lean structure suggests a fast-track development cycle where the company maintains full control over the proprietary technology and IP, though it lacks academic or large-scale industrial partners within the EU consortium.
Contact Novelrad Ltd in Israel regarding Class III medical device partnerships.
Contact us to explore licensing opportunities for micro-suturing technology.
